14 publications with more than 100 citations including;
Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine use. Clin Exp Dermatol 1994; 19:210-216. (725 Citations)
Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. British Journal of Dermatology 1995; 132; 236-244. (263 Citations)
262 publications and 221 published abstracts
Hirsch Index = 38 (38 articles with 38 or more citations)
Key Research Publications 2000 - 2009
Harper J I, Ahmed I, Barclay G, Lacour M, Hegger P, Cork M J, Finlay A Y, Wilson N J E, Graham-Brown R A C, Sowden J M, Beard A L, Sumner M J, Berth-Jones J. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. British Journal of Dermatology 2000; 142: 52-58.
Harlow D, Poyner T, Finlay A Y, Dykes P J,. Impaired quality of life of adults with skin disease in primary care. British Journal of Dermatology 2000; 143: 979-982.
Lewis-Jones M S, Finlay A Y, Dykes P J. The infant’s dermatitis quality of life index. British Journal of Dermatology 2001; 144: 104-110.
Touw C R, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten F F H, Finlay A Y. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. British Journal of Dermatology 2001; 144: 967-976.
Williamson D, Gonzalez M, Finlay A Y. The effect of hair loss on quality of life. Journal of the European Academy of Dermatology & Venereology 2001; 15: 137-139.
Chave T A, Finlay A Y, Knight A G on behalf of the All-Wales Dermatology Audit Committee. Thalidomide usage in Wales: the need to follow guidelines. British Journal of Dermatology 2001; 144: 310-315.
Fivesson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. Managed Care Pharmacy 2002; 8: 333-342.
Salek M S, Finlay A Y. Quality of life in patients with severe psoriasis receiving cyclosporin: A multi-centre study. Journal of Applied Therapeutic Research 2003; 4: 3-10.
Loo W-J, Diba V, Chawla M, Finlay A Y. Dermatology life quality index: influence of an illustrated version. British Journal of Dermatology 2003; 144: 279-284.
Holmes S A, Man I, Sharpe J L, Dykes P J, Lewis-Jones MS, Finlay A Y. The Children’s Dermatology Life Quality Index: Validation of the cartoon version. British Journal of Dermatology 2003; 148:285-290.
Finlay A Y, Salek M S, Haney J. For the Alefacept Clinical Study Group. Intramuscular Alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206: 307-315.
Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: a comparative study. J Am Acad Dermatol 2003; 49: 249-254.
Salek M S, Finlay A Y, Lewis J J C, Sumner M I. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Quality of Life 2004; 13: 91-95.
Dreno B, Finlay A Y, Nocera T, Verrière F, Taïeb C, Myon E. CADI: Cultural and linguistic validation into French of an acne disability index. Dermatology 2004; 208: 104-108.
Szepietowski J, Salomon J, Finlay A Y, Klepacki A, Chodynicka B, Marionneau N, Taïeb C, Myon E. Dermatology Life Quality Index: Polish version. Dermatologia Kliniczna 2004; 6: 63-70.
Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay A Y. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatology 2004; 4: 8.
Lewis V, Finlay A Y. Ten years experience of the Dermatology Life Quality Index (DLQI). Journal of Investigative Dermatology Symposium Proceedings 2004; 169-180.
Griffiths C E M, Dubertret L, Ellis C N, Finlay A Y, Finzi A F, Ho V C, Johnston A, Katsambas A, Lison A-E, Naeyaert J M, Nakagawa H, Paul C, Vanaclocha F. Ciclosporin in psoriasis clinical practice: An international consensus statement. British Journal of Dermatology 2004; 150 (Suppl 67): 11-23.
Katugampola R P, Hongbo Y, Finlay A Y. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol 2005; 152: 1256-1262.
Hongbo Y, Thomas C L, Harrison M A. Salek M S, Finlay A Y. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Investig Dermatol 2005; 125: 659-664.
David S E, Ahmed Z, Salek M S, Finlay A Y. Does enough quality of life-related discussion occur during dermatology out-patient consultations? Br J Dermatol 2005; 153: 997-1000.
Krueger G G, Langley R G, Finlay A Y, Griffiths C E M, Woolley J M, Lalla D, Jahreis A. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomised Phase III trial. Br J Dermatol 2005; 153: 1192-1199.
Finlay A Y. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005; 152: 861-867.
Lewis V J, Finlay A Y. Two decades experience of the Psoriasis Disability Index. Dermatology 2005; 210: 261-268.
Smith C H, Anstey A V, Barker J N W N, Burden A D, Chalmers R J G, Chandler D, Finlay A Y, Griffiths C E M, Jackson K, McHugh N J, McKenna K E, Reynolds N J, Ormerod A D. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.
Br J Dermatol 2005; 153: 486-497.
Gilani S J K, Gonzalez M, Hussain I, Finlay A Y, Patel G K. Staphylococcus aureus re-colonization in atopic dermatitis: Beyond the Skin. Clinical & Experimental Dermatology 2005; 30: 10-13.
Gillard S E, Finlay A Y. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource in primary care. International Journal of Clinical Practice 2005; 59: 1260-1267.
Holme S A, Anstey A V, Finlay A Y, Elder G H, Badminton M N. Erythropoietic protoporphyria in the UK: clinical features and effect on quality of life. Br J Dermatol 2006; 155: 374-381.
Takahashi N, Suzukamo Y, Kakamura M, Miyachi Y, Green JH, Ohya Y, Finlay A Y, Fukuhara S
Japanese version of the Dermatology Life Quality Index: validity and reliability in patients with acne. Health Qual Life Outcomes 2006; 4(1): 46 (e-pub)
Patel G K, Wilson C H, Harding K G, Finlay A Y, Bowden P E. Numerous keratinocyte subtypes involved in would re-epithelialisation. J Invest Dermatol 2006; 126 (2): 497-502
Katugampola R P, Finlay A Y. Oral retinoid therapy for disorders of keratinization: Single-centre retrospective 25 years’ experience on 23 patients. Br J Dermatol 2006; 154: 267-276.
Patel G K, Goodwin R, Chawla M, Laidler P, Price P P, Finlay A Y, Motley R J. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s Disease): A randomised, double-blind, placebo-controlled trial. JAAD 2006; 54: 1025-1032.
Griffiths C E, Finlay A Y, Fleming C J, Barker J N, Mizzi F, Arsonnaud S. A randomised investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatological Treatment 2006; 17: 90-95.
Kellett N, West F, Finlay A Y. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial. Br J Dermatol 2006; 154: 524-532.
Basra M K A, Sue-Ho R, Finlay A Y. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007; 156: 528-538.
Katugampola R P, Lewis V J, Finlay A Y. The Dermatology Life Quality Index: assessing the efficacy of biologic therapies for psoriasis. Br J Dermatol 2007; 156: 945-950.
Basra M K A, Finlay A Y. The family impact of skin diseases: the Greater Patient concept. Br J Dermatol 2007; 156: 929-937.
Eghlileb A M, Davies E E G, Finlay A Y. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol 2007; 156: 1245-1250.
Salek S, Roberts A, Finlay A Y. The practical reality of using a patient referred outcome measure in a routine dermatology clinic. Dermatology 2007; 215: 315- 319.